NCT05375214已完成不适用
A Pilot Study of iTBS in Bipolar I Depression
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 4
- 主要终点
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
研究概览
简要总结
A multisite, open label pilot study to investigate the efficacy and safety of a novel accelerated intermittent theta-burst stimulation (iTBS) protocol while assessing for changes in neuroimaging biomarkers associated with treatment response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •22-65 years of age
- •Bipolar I disorder diagnosis as defined by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- •Currently experiencing a Major Depressive Episode with Montgomery-Asberg Depression Rating Scale (MADRS) >/= 20 at screening [Day -5/-14] and baseline [Day 0]
- •On a stable and adequate dose of an anti-manic agent (Lithium with a level of at least 0.6, Depakote with a level of at least 50, or a therapeutic dose of carbamazepine, oxcarbazepine, or a neuroleptic for treatment of mania per clinician judgment) without dose changes for at least 6 weeks prior to the active study time period. Final assessment of appropriateness of participant's pharmacologic regimen is subject to study team clinician judgment.
- •Having failed a therapeutic trial of a first line bipolar depression antidepressant (as specified by the Antidepressant Treatment History Form and updated with new medications approved by the FDA for treatment of bipolar depression) in this current episode. This includes a minimum 4 week trial of one of the following medications (minimum dosage): lithium 900mg daily (or blood level >= 0.6 milliequivalent/Liter (mEq/L), carbamazepine 400mg daily (or blood level >= 0.8 mEq/L), lamotrigine 200mg daily, asenapine 20mg daily, lurasidone 20mg daily, olanzapine 10mg daily, quetiapine 300mg daily, or lumateperone 42mg daily. Final determination of a failed adequate therapeutic trial is subject to study team clinician judgement.
- •Established outpatient psychiatrist
排除标准
- •Female that is pregnant or breastfeeding, or of childbearing potential but not using medically acceptable birth control during study
- •Current mixed episode assessed by clinician judgment as defined by DSM-5 criteria
- •Current active substance use disorder (as defined by DSM-5) with exception of nicotine and caffeine. Participants may be subject to urine drug screen base on study team clinician judgment.
- •Participation in any clinical trial with an investigational drug or device within the last 3 month or concurrent to study participation
- •History of epilepsy, shrapnel or metal in the head or skull, cardiovascular disease/event, Obsessive Compulsive Disorder, or autism spectrum disorder
- •Clinically defined major neurological disorder; including, but not limited to, seizure disorder and history of loss of consciousness due to head injury for greater than 10 minutes, or documented evidence of brain injury
- •Active suicidal risk based on investigator's clinical judgment
- •Clinically significant unstable medical condition
- •Other condition judged by investigator that could prevent the participant from completion of the study (such as but not limited to, significant physical disability (e.g., hearing/visual deficits) to perform a neutral memory task and/or neuropsychological test battery)
- •Ferromagnetic metal implant or another contraindication to imaging in a 3 Tesla MRI
- •Electroconvulsive therapy (ECT) treatment in the past 3 months
- •Minimum of 6 months since last manic or hypomanic episode as defined by DSM-5 criteria
结局指标
主要结局
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
时间窗: baseline and post treatment up to 5 days
The MADRS is a ten-item clinician rated questionnaire that helps rate the severity of depression. Total scores can range from 0 to 60, with higher scores indicating greater severity of depression (0-6 normal range, 7-19 mild depression, 20-34 moderate depression, \>34 severe depression). MADRS score will be assessed at baseline visit and immediate follow-up visit (which occurs within 5 days after treatment end). The change in MADRS score is calculated by baseline - immediate follow-up visit score.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)Ovarian NeoplasmsNCT01329549Boehringer Ingelheim2
已完成
1 期
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid TumorsSolid TumorsNCT00555724Biogen40
招募中
1 期
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsNon-Small Cell Lung Cancer (NSCLC)NCT05271916Shanghai Chest Hospital140
已完成
1 期
A Study of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT05442788Huabo Biopharm Co., Ltd.30
已完成
1 期
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisANCA-associated VasculitisNCT05197842Staidson (Beijing) Biopharmaceuticals Co., Ltd93